Cargando…

Avelumab in metastatic collecting duct carcinoma of the kidney: a case report

BACKGROUND: Collecting duct carcinoma (CDC) of the kidney is associated with an aggressive course, limited response to treatment, and poor prognosis. Platinum-based chemotherapy is currently recommended as the first-line treatment in patients with metastatic CDC. Accumulating evidence supports the u...

Descripción completa

Detalles Bibliográficos
Autores principales: Pyrgidis, Nikolaos, Sokolakis, Ioannis, Haltmair, Gena, Heller, Vitus, Hatzichristodoulou, Georgios
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10262369/
https://www.ncbi.nlm.nih.gov/pubmed/37308983
http://dx.doi.org/10.1186/s13256-023-03973-3
_version_ 1785058044742205440
author Pyrgidis, Nikolaos
Sokolakis, Ioannis
Haltmair, Gena
Heller, Vitus
Hatzichristodoulou, Georgios
author_facet Pyrgidis, Nikolaos
Sokolakis, Ioannis
Haltmair, Gena
Heller, Vitus
Hatzichristodoulou, Georgios
author_sort Pyrgidis, Nikolaos
collection PubMed
description BACKGROUND: Collecting duct carcinoma (CDC) of the kidney is associated with an aggressive course, limited response to treatment, and poor prognosis. Platinum-based chemotherapy is currently recommended as the first-line treatment in patients with metastatic CDC. Accumulating evidence supports the use of immunotherapy with checkpoint inhibitors as second-line therapy. CASE PRESENTATION: In this case report, we describe the first case of avelumab administration due to disease progression during chemotherapy with gemcitabine and cisplatin in a Caucasian, 71-year-old man presenting with multiple metastases due to CDC of the kidney. The patient initially responded well to four cycles of chemotherapy and his performance status improved. After two additional chemotherapy cycles, the patient presented with new bone and liver metastases (mixed response to chemotherapy with an overall 6-month progression-free survival). We offered him avelumab as a second-line treatment in this setting. The patient received a total of three cycles of avelumab. The disease remained stable (no new metastases during treatment with avelumab), and the patient developed no complications. To alleviate his symptoms, radiation therapy for the bone metastases was decided. Despite successful radiation of the bone lesions and further improvement of symptoms, the patient developed hospital-acquired pneumonia and died approximately ten months after the initial diagnosis of CDC. CONCLUSIONS: Our findings suggest that the applied treatment modality with gemcitabine and cisplatin chemotherapy followed by avelumab was effective in terms of both progression-free survival and quality of life. Still, further studies assessing the use of avelumab in this setting are mandatory.
format Online
Article
Text
id pubmed-10262369
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-102623692023-06-15 Avelumab in metastatic collecting duct carcinoma of the kidney: a case report Pyrgidis, Nikolaos Sokolakis, Ioannis Haltmair, Gena Heller, Vitus Hatzichristodoulou, Georgios J Med Case Rep Case Report BACKGROUND: Collecting duct carcinoma (CDC) of the kidney is associated with an aggressive course, limited response to treatment, and poor prognosis. Platinum-based chemotherapy is currently recommended as the first-line treatment in patients with metastatic CDC. Accumulating evidence supports the use of immunotherapy with checkpoint inhibitors as second-line therapy. CASE PRESENTATION: In this case report, we describe the first case of avelumab administration due to disease progression during chemotherapy with gemcitabine and cisplatin in a Caucasian, 71-year-old man presenting with multiple metastases due to CDC of the kidney. The patient initially responded well to four cycles of chemotherapy and his performance status improved. After two additional chemotherapy cycles, the patient presented with new bone and liver metastases (mixed response to chemotherapy with an overall 6-month progression-free survival). We offered him avelumab as a second-line treatment in this setting. The patient received a total of three cycles of avelumab. The disease remained stable (no new metastases during treatment with avelumab), and the patient developed no complications. To alleviate his symptoms, radiation therapy for the bone metastases was decided. Despite successful radiation of the bone lesions and further improvement of symptoms, the patient developed hospital-acquired pneumonia and died approximately ten months after the initial diagnosis of CDC. CONCLUSIONS: Our findings suggest that the applied treatment modality with gemcitabine and cisplatin chemotherapy followed by avelumab was effective in terms of both progression-free survival and quality of life. Still, further studies assessing the use of avelumab in this setting are mandatory. BioMed Central 2023-06-13 /pmc/articles/PMC10262369/ /pubmed/37308983 http://dx.doi.org/10.1186/s13256-023-03973-3 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Case Report
Pyrgidis, Nikolaos
Sokolakis, Ioannis
Haltmair, Gena
Heller, Vitus
Hatzichristodoulou, Georgios
Avelumab in metastatic collecting duct carcinoma of the kidney: a case report
title Avelumab in metastatic collecting duct carcinoma of the kidney: a case report
title_full Avelumab in metastatic collecting duct carcinoma of the kidney: a case report
title_fullStr Avelumab in metastatic collecting duct carcinoma of the kidney: a case report
title_full_unstemmed Avelumab in metastatic collecting duct carcinoma of the kidney: a case report
title_short Avelumab in metastatic collecting duct carcinoma of the kidney: a case report
title_sort avelumab in metastatic collecting duct carcinoma of the kidney: a case report
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10262369/
https://www.ncbi.nlm.nih.gov/pubmed/37308983
http://dx.doi.org/10.1186/s13256-023-03973-3
work_keys_str_mv AT pyrgidisnikolaos avelumabinmetastaticcollectingductcarcinomaofthekidneyacasereport
AT sokolakisioannis avelumabinmetastaticcollectingductcarcinomaofthekidneyacasereport
AT haltmairgena avelumabinmetastaticcollectingductcarcinomaofthekidneyacasereport
AT hellervitus avelumabinmetastaticcollectingductcarcinomaofthekidneyacasereport
AT hatzichristodoulougeorgios avelumabinmetastaticcollectingductcarcinomaofthekidneyacasereport